# Baohui Han

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/baohui-han/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15,187 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 281 |
| Last Known Institution | Shanghai Jiao Tong University |
| OpenAlex ID | https://openalex.org/A5021139793 |
| ORCID iD | 0000-0002-3950-3030 |
| Works | 686 |

## Researcher papers

- [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-anlotinib-as-a-third-line-or-further-treatment-on-overall-survival-of/)
- [Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: A systematic review and meta-analysis](https://scholariq.org/papers/endobronchial-ultrasound-guided-transbronchial-needle-aspiration-for-staging-of/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)
- [A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese](https://scholariq.org/papers/a-genome-wide-association-study-identifies-two-new-lung-cancer-susceptibility/)
- [First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study](https://scholariq.org/papers/first-line-icotinib-versus-cisplatin-pemetrexed-plus-pemetrexed-maintenance/)
- [Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer](https://scholariq.org/papers/genomic-landscape-survey-identifies-srsf1-as-a-key-oncodriver-in-small-cell-lung/)
- [Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)](https://scholariq.org/papers/anlotinib-as-a-third-line-therapy-in-patients-with-refractory-advanced-non-small/)
- [Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer](https://scholariq.org/papers/allogeneic-v-9v-2-t-cell-immunotherapy-exhibits-promising-clinical-safety-and/)
- [Characteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitor treatment](https://scholariq.org/papers/characteristics-and-outcome-of-small-cell-lung-cancer-patients-sclc-transformed/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Shanghai Jiao Tong University](https://scholariq.org/institutions/shanghai-jiao-tong-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.